Biocartis is an innovative commercial stage molecular diagnostics (MDx) company providing next generation diagnostic solutions aimed at improving clinical practice for the benefit of patients, clinicians, payers and industry. The Company’s proprietary MDx Idylla™ platform is a fully automated, real time system which offers accurate, highly-reliable molecular information from any biological sample in virtually any setting. Idylla™ addresses the growing demand for personalized medicine by allowing fast and effective treatment selection and treatment progress monitoring. Biocartis is developing and marketing a rapidly expanding test menu addressing key unmet clinical needs in oncology and infectious diseases. These areas represent respectively the fastest and largest growing segments of the US$5 billion MDx market1 which is expected to grow to approximately US$8 billion in 2018.
Mechelen, BE
Size (employees)
278 (est)
Biocartis was founded in 2007 and is headquartered in Mechelen, BE

Key People/Management at Biocartis

Ulrik Cordes

Ulrik Cordes

Chief Commercial Officer
Chris Gabriels

Chris Gabriels

Director of Operations

Biocartis Office Locations

Biocartis has an office in Mechelen
Mechelen, BE (HQ)
11 Generaal de Wittelaan

Biocartis Financials and Metrics

Biocartis Financials


Market capitalization (22-Mar-2017)

440.5 b

Closing share price (22-Mar-2017)

Biocartis's current market capitalization is €440.5 b.
Show all financial metrics

Biocartis Market Value History

Biocartis's Web-traffic and Trends

Biocartis Online and Social Media Presence

Biocartis Company Life and Culture

You may also be interested in